Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Caremark May Offer "Open" Medicare Rx Plan In Some Regions

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharmacy benefit manager is deciding whether to offer standalone drug plans in regions in which it does not have employer or health plan partners, CEO Crawford says. The exec notes some of Caremark's clients will "aggressively" market their plans to individuals for 2006.

You may also be interested in...



Caremark Anticipates Modest Uptake For Medicare Rx Benefit In 2006

The PBM expects enrollment may not rise significantly until 2010 or later. Beneficiary participation in Part D could mirror the slow uptake of the drug discount card, CEO Crawford says, asserting that seniors "don't understand" the new benefit.

Caremark To Join Medco In Applying To Be National Medicare Rx Sponsor

Assuming both PBMs are approved as national Part D sponsors, there will be no need for “fallback” plans in 2006. Caremark, like Medco, is stressing a desire to sell Part D through health plan and employer clients.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062295

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel